Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
SLU-PP-332 is a research compound sold for laboratory and research use only
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
86 (5): 1563S1568S
Bacteriostatic water is a US-centric product and is not routinely stocked or licensed as a standard diluent in the UK, where Water for Injections BP is the standard
This marks another step forward in building a late-stage pipeline for psychedelic-based treatments
But what are the real benefits, and who can truly benefit from this treatment
